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Abstract
Background: The neurotensin (NTS) and its specific high affinity G protein coupled receptor, the NT1 receptor (NTSR1), are
considered to be a good candidate for one of the factors implicated in neoplastic progression. In breast cancer cells,
functionally expressed NT1 receptor coordinates a series of transforming functions including cellular migration and invasion.
Methods and Results: we investigated the expression of NTS and NTSR1 in normal human breast tissue and in invasive
ductal breast carcinomas (IDCs) by immunohistochemistry and RT-PCR. NTS is expressed and up-regulated by estrogen in
normal epithelial breast cells. NTS is also found expressed in the ductal and invasive components of IDCs. The high
expression of NTSR1 is associated with the SBR grade, the size of the tumor, and the number of metastatic lymph nodes.
Furthermore, the NTSR1 high expression is an independent factor of prognosis associated with the death of patients.
Conclusion: these data support the activation of neurotensinergic deleterious pathways in breast cancer progression.
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Introduction
Breast cancer is the most frequent cause of cancer-related
deaths among women in the western world [1]. Among these
patients, one of four women dies from breast cancer, despite
improvements in diagnosis, surgery, chemotherapy and the new
targeted therapies. Death is associated with the metastatic
development of the disease. The discovery and characterization
of new contributors remain necessary in order to develop
appropriate and highly specific treatments targeted to metastasis
initiation and progression processes.
Neurotensin (NTS) is a 13 amino acids peptide formed from a
large precursor, cleaved by convertases. NTS is commonly known
for its distribution along the gastrointestinal tract [2]. Typical
physiological functions for NTS include stimulation of pancreatic
and biliary secretions, inhibition of small bowel and gastric motility,
and facilitation of fatty acids translocation [3–5]. NTS was equally
reported in functions linked specifically to neoplastic progression,
including proliferation of the pancreas, prostate, colon, and lung
cancer cells [6]. We have previously described detrimental effects,
caused by NTS, on xenografted breast tumor growth as well as
migration, invasion, and survival of breast cancer cells [7,8].
NTS expression is also found in endocrine tumors and is linked
to tissue differentiation [9]. NTS is expressed in fetal colon,
repressed in newborn and adult colon, and re-expressed in
approximately 25% of human colon cancers due to epigenetic
mechanisms linked to NTS gene hypomethylation [10].
NTS peripheral functions are mediated through its interaction
with the NTSR1 [11]. When NTSR1 is challenged with NTS,
phosphatidyl inositols are hydrolyzed leading to Ca
2+ mobilization
and PKC, ERK1/2, RhoGTPases, NFkappa-B, and focal
adhesion kinase (FAK) activation [12–15]. The NTSR1 gene is
a target of the Wnt/APC oncogenic pathways connected with the
b-catenin/Tcf transcriptional complex, known to activate genes
involved in cancer cell proliferation and transformation [7].
In this report, we investigate the expression of NTS and NTSR1
in a cohort of 106 women diagnosed for invasive ductal breast
cancer (IDCs). We conclude that NTSR1 regulation may occur in
breast cancer and participates in the neoplastic progression in up
to 35% of all patients.
Results
NTS expression in normal epithelial breast cells is
regulated by estradiol
The NTS gene was previously described as an estradiol target
gene [16] with estradiol increasing NTS transcription in the
preoptic area and neurosecretory cells of the hypothalamic arcuate
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normal human breast tissue, and studied NTS transcript on normal
mammary glands, and on eight different human breast epithelial
cells (HBEC) cultures. We consistently detected NTS amplicon with
low to medium intensity. Typical examples are shown in figure 1A
left. In order to evaluate if NTS gene is also regulated by estradiol in
human breast, HBEC were exposed to estradiol. As shown in
figure 1A right, an enhancement of NTS transcripts was observed.
This effect was abolished when ICI 182780, a pure anti-estrogen,
was added concomitantlytoestradiol (Figure 1Aright) suggesting that
estrogen receptors participate in the NTS gene regulation in human
breast tissue. Corroborating these results, NTS expression was
positively detected by immunohistochemistry in 19 (76%) biopsies of
normal breast tissues from 25 premenopausal women. We observed
NTS labeling within sparse epithelial cells of ducts and lobules
(Figure 1B, 1 and 4). On the same slide we noticed that the lobular
structures were labeled with a more intense staining than the duct
structures. We also noticed that the normal adjacent tissue of
invasive ductal breast carcinomas (IDCs) was very often labeled by
NTS antibody, with similar intensity and cellular distribution as in
the tissue from healthy women (Figure 1B, 5 and 6).
NTS expression in invasive ductal breast carcinomas
We previously demonstrated the presence of NTSR1 and NTS
expression in breast ductal carcinomas, along with NTS induced
effects on tumor growth, cellular mobility and collagen invasion of
Figure 1. Neurotensin expression in normal breast tissue. a) Left, one mg of total RNA from HBEC or whole gland were reverse-transcribed and
a PCR experiment specific for NTS was performed. Right, one mg of total RNA from HBEC cells (control, treated with 10 nM estradiol (E2) with or
without 1 mM ICI 182780) was reverse-transcribed. A PCR experiment was performed using specific primers for NTS and GAPDH. b) Normal duct
exposed to NTS antibody at 1/500 dilution (1), after pre-incubation with the antigen peptide for 2 h at 10 nM (2), or without primary antibody (3), and
lobule exposed to NTS antibody (4). Normal tissue exposed to NTS antibody at 1/500 dilution adjacent to tumor duct (5), lobule (6). The original
magnification was 2006.
doi:10.1371/journal.pone.0004223.g001
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status ofNTS and NTSR1inbreast cancerwestudiedtheir respective
expression in 106 IDCs. Details of clinical data, pathological
characteristics, and treatment modulations are shown in table 1.
NTS was graded in the invasive and ductal components in the
patients’ IDCs. In most cases a large amount of cells were positively
labeled with NTS antibody (Figure 2A). NTS positive labeling in
invasive component is significantly correlated with the positive
labeling in the ductal component (P=0.004). In both cases, NTS
labeling was cytosolic (Figure 2A). Using RT-PCR, we confirmed the
high expression of NTS transcript in 9 of 11 breast cancer tissues
(Figure 2B). Five patients exhibited a very strong expression of NTS
transcript (Figure 2B, lane 2–6) and four others displayed a weaker
expression (Figure 2B, lane 7–9 and 11). No correlation was observed
with prognosis factors and disease progression (tumor size, grade,
number of invaded nodes, recurrence, and death) with NTS
expression, neither in the ductal nor in the invasive components
(Table 2). The only correlation found, was between PR and NTS
expression in the invasive component. NTS is neither a marker nor
associated with tumor progression in breast cancer.
NTSR1 expression in IDCs
NTSR1 staining in IDCs showed that NTSR1 expression was
spread throughout many tumor cells in the invasive and ductal
components. The labeling was granular and mostly cytosolic. In the
invasive component of studied IDCs, the majority exhibited a high
proportion of NTSR1 positive cells (from 50 to 100%). We
hypothesized that the deleterious effects ofNTS previouslydescribed
should occurintumors containing a very high proportion of NTSR1
expressing cells [7,19]. We focused on the 35% of patients in which
80% or more of the tumor cells expressed the NT1 receptor.
Expression of NTSR1 was verified by RT-PCR on frozen tissues
from 11 patients. As shown in Figure 2B, three patients expressed
NTSR1(lane3,6,9)withtwoshowingaveryhighampliconamount
(Figure 2B lane 6, 9).
The characteristics of the women exhibiting high NTSR1
expression ($80% of tumor cells) are shown in table 3. High
NTSR1 expression was associated with a larger tumor size
(p,0.01), SBR grade 3 (p,0.05), the number of positive lymph
nodes (p,0.05), and as a consequence it was also associated with
chemotherapy (p,0.01). Using univariate analysis we found that
patients with high expression of NTSR1 had a significantly worse
prognosis than those with low NTSR1 expression (ten years
survival rate of 66.2% versus 96.5%; p=0.01). Kaplan-Meier
survival graph up-to 10 years, and number of patients at risk
during this period of time are shown in figure 3. Multivariate
analysis with a Cox model adjusted for major prognosis risk
factors, age, tumor size, SBR grade, positive ER status and lymph
nodes, showed that high NTSR1 expression remained an
independent prognosis marker. The relative risk of dying in
women with expression of NTSR1$80% compared to women
with expression of NTSR1,80% was significantly increased
(RR=5.29, 95% confidence interval [1.04–26.88], p=0.044).
NTSR1 paracrine regulation
Within the 48 patients expressing NTS in the invasive
component, 20 (42%) exhibited high expression of NTSR1
($80%), corresponding to 20% of the whole population.
Examining adjacent tissue sections of these patients, a clear
regional co-localization of the ligand and its receptor was detected
in all IDCs (Figure 2C). Within the population co-expressing NTS
and NTSR1 the distribution among the SBR grades was altered as
compared to the total population, with few patients in the grade 1
and most patients in the grade 3 (p,0.05). The size of the tumor,
the recurrence and the number of death were higher in this
subpopulation than in the total population. In addition, the ER
alpha receptor positivity, characterized as a differentiated and
good prognosis marker, was correlated with the NTS and low
NTSR1 expression (p,0.05) (Table 4).
NTSR1 and NTS gene expression in breast cancer
microarray studies
We sought to compare our findings with those from publically
available breast gene array analysis. A correlation between up
regulated expression of NTSR1 with the higher grades was found
studying 55 and 125 breast carcinomas, from the Ginestier and
Sotiriou databases (p=0.028 and 0.04), respectively [20,21]. In
the Chin gene profile, containing 118 frozen primary breast
carcinomas, NTSR1 was found over expressed in stage IV
carcinomas as compared to stage I with p=0.003. In the same
study, a correlation between NTSR1 over expression and the
positive lymph node status was found (p=0.04) [22]. No
correlation was detected in the available databases between the
over expression of NTSR1 and 5-year survival, noting that data
were not available for longer time periods. The latter result is
unsurprising, because of the very low number of deaths registered
in these small populations during a survival time frame which is
shorter than that observed in breast cancer patients managed with
Table 1. Patients clinical characteristics.
IDCs
n=106
Age in years [mean6SD] 57.96614.04
Menopausal status
Post menopausal patients [n (% of patients)] 69 (65%)
Age at menopause [mean6SD] 50.9663.05
Family history of breast cancer [n/number of cases studied
(% of patients)]
18/79 (23%)
HRT use [n/number of cases studied (% of patients)] 17/92 (18%)
Follow-up in months [mean6SD] 67.9641.93
Positive estrogen receptor [n/number of cases studied (% of
patients)]
69/100 (69%)
Positive progesterone receptor [n/number of cases studied
(% of patients)]
71/99 (71.7%)
Tumor size (cm) [mean6SD] 2.361.43
SBR grade [n]
13 3
24 9
32 4
Number of patients N+ [n/number of cases studied (% of
patients)]
42/104 (40.4%)
Number of invaded nodes [mean6SD] 1.3262.55
Recurrence during follow-up [n (% of patients)] 26 (25%)
Deaths during follow-up [n (% of patients)] 11 (10.4%)
Adjuvant therapy (number of cases studied) 102
Radiotherapy [n (% of patients)] 96 (94%)
Chemotherapy [n (% of patients)] 36 (35.5%)
Tamoxifen use [n (% of patients)] 78 (76.4%)
SBR; Scarff Bloom and Richardson, n=number of patients, SD=standard
deviation.
doi:10.1371/journal.pone.0004223.t001
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correlation between survival and NTSR1 expression was strongest
at the 10-year follow-up (p=0.01) and decreased with shortening
of it, arriving at a value of 0.052 (NS) at the 5-year follow-up. Of
note, studies using other parameters confirm that the NTSR1
expression is a poor prognosis marker. in the ‘‘Ma’’ database
studying 54 patients with breast carcinomas, NTSR1 is correlated
with the recurrence at 5 years (p=0.04) [23]. In Chang’s study,
dealing with 24 breast ductal carcinomas classified according to
the docetaxel response, NTSR1 was more intensively expressed in
the group resistant to this chemotherapy agent [24].
A high correlation was found between NTS and estrogen
receptor expression in the Sotiriou and Chin gene arrays ( p=7.9
E-5 and 0.002, respectively [21,22]). In the Chin gene array, NTS
expression was also correlated with progesterone receptor
expression (p=0.003). As in our study, no other correlation was
detected. The results reported here and those from the gene array
profiles lead, therefore, to similar conclusions.
Discussion
This paper evaluates the status of NTSR1 as a contributor in
human breast cancer progression. One approach to address this
question is to determine if paracrine NTS regulation is associated
with the patients’ poor outcome. We suspected that the
contribution of NTSR1 in tumorigenesis occurred from local
and sustained activation of the receptor rather than from
circulating NTS, because NTS is a highly degradable peptide
and its blood concentration rapidly drops after its release. It has
been demonstrated that sustained activation of NTSR1 results in
persistent NTSR1 recycling as well as signalization activation,
including ERK1/2 [19], and causes sustained gene activation of
MMP9 and Bcl-2 [7,8]. In human tumor these conditions would
be satisfied if NTS is synthesized and released within the vicinity of
NTSR1 expressing cells. NTSR1 expression is an early event of
cell transformation, because of the resulting NTSR1 promoter
activation by the Wnt/b-catenin pathway [25]. Here we showed
that NTSR1 is highly expressed ($80%) in 35% of the patients
with a granular labeling mostly cytosolic suggesting an intense
receptor endocytosis.
The data concerning NTS expression in human cancer are
sparse. Hypomethylation, or NTS regulation by Ras or Src
oncogenes were described as possible mechanisms leading to
expression of NTS gene in cancer [10]. Hormonal regulation was
also described more specially in specific areas of the hypothalamus,
and in the preoptic area, where NTS mRNA is stimulated by
Figure 2. Neurotensin expression in IDCs. a) NTS immunohistochemistry was performed on IDCs, ductal (1) and invasive (2) components,
magnification 2006for (1) and 4006for (2). b) NTS and NTSR1 transcripts in IDCs. One mg of total RNA from 11 patients with IDCs were reverse-
transcribed, and specific PCR was performed for NTS, NT-1 receptor, or GAPDH (control). The SBR grade is indicated below each line. c) Example of
NTS and NTSR1 regional co-localization by immunohistochemistry for NTS (right) and NTSR1 (left) at the original magnification 4006.
doi:10.1371/journal.pone.0004223.g002
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protein kinase A-dependent signaling mechanisms [16]. In this
paper we observed the expression of NTS and NTS mRNA in
HBEC and demonstrated that NTS is an estrogen target gene in
those cells. We also observed expression of NTS in tumor cells of
the ductal and invasive components in breast IDCs, with a strong
statistical correlation of NTS expression in both components. This
latter finding, with a similar NTS repartition within the low or
high NTSR1 expressing patients, suggests that NTS gene remains
constitutively expressed during the neoplastic process, rather than
being deregulated. In parallel, we observed a frequent regional co-
localization of both markers in adjacent tissue sections from the
same tumor, suggesting NTSR1 activation. Together with the
expression of NTSR1, these data validate our hypothesis of the
NTS paracrine regulation of transformed epithelial cells during
the neoplastic process, with NTS released from the surrounding
normal breast tissue or from the breast tumor.
High NTSR1 expression was significantly associated with the
SBR grade, the size of the tumor, and the number of metastatic
lymph nodes, and ultimately with death of the patients. These
findingssupportthedeleteriouseffectsofNTSfoundinbreastcancer
cells [7]. NTS and NTSR1 are implicated in several detrimental
functions linked to the neoplastic progression, including proliferation
of the pancreas, prostate, colon and lung cancer cells [6], protection
of breast cancer cells against apoptosis [8], and induction of the
proinvasive potential of colon cancer cells [25]. More recently, it was
shown that NTSR1 activation results in EGFR transactivation by
the shedding of transforming growth factor-a (TGF-a) in pancreas,
and HB-EGF or amphiregulin in prostate cancer cells, both leading
to ERK1/2 activation [27], but also EGFR expression [28]. These
findings point out that the poor prognosis attributed to patients with
highly NTSR1 expressing IDCs may be directly related to the
expression of its natural ligand NTS, with the continuous activation
of the NTSR1, leading to enhanced cancer cell survival, invasiveness
potential, and metastasis [7,8].
In conclusion, based on a series of 106 patients with invasive
ductal breast cancer, we provide evidence for NTS/NTSR1 as a
contributor to breast cancer progression. Identification of breast
cancer patients characterized by paracrine NTS/NTSR1 signal-
ing pathway, as evidenced in the present study, will provide
alternative strategies to improve the treatment of IDCs. These
findings support the therapeutic potential of NTS/NTSR1
inhibition or drug cellular targeting through NTSR1 in advanced
stages of human breast cancers.
Materials and Methods
Breast Biopsies
Clinical file of 106 patients completely resected for invasive
ductal breast cancers (IDCs) by tumorectomy or mastectomy, at
the Gynecology Department, Ho ˆtel-Dieu Hospital, Paris, were
studied. Patients were diagnosed by the same oncologist (Dr Y.
Decroix) for a period from June 1984 through May 1998. Clinico-
pathological information was derived retrospectively from patient
records. Survival and follow-up durations were measured as the
time between the first histological confirmation of breast cancer
and the last consultation in the department, or death. Patient
records were reviewed retrospectively for demographical charac-
teristics, clinical data, outcome, and survival. The histological
diagnosis was routinely checked by microscopic examination of
sections stained with hematoxylin-eosin.
Ethics
The following studies were conducted on tissues obtained from
patients between 1984 and 1998. The experiments reported here
were carried out under the current French ethical regulations as
Table 2. Prognosis factors and deaths stratified by NT expression in the ductal and invasive components of IDCs.
NT NT
Ductal component Invasive component
n=87 n=103
NO YES P NO YES P
n=31 n=56 n=55 n=48
Positive estrogen receptor [n/number of cases studied (SD)] 30/49 36/47 NS
Positive progesterone receptor [n/number of cases studied (SD)] 32/51 37/45 0.034
Tumor size (cm) [number of cases studied] 30 52 54 44
[mean6SD] 2.3661.7 2.2261.25 NS 2.4361.7 2.0360.9 NS
SBR grade [number of cases studied] 31 56 52 47
1 7 21 16 17
2 1 32 6 2 52 2
3 11 9 NS 14 9 NS
Number of Invaded nodes [number of cases studied] 30 54 52 48
[mean6SD] 1.1762.3 1.6663 NS 1.2362 1.4963N S
Recurrence during follow-up [n/n of patient studied] 6/31 14/56 NS 15/55 11/47 NS
Deaths during follow-up [n/n of patients studied] 2/31 7/56 NS 5/55 6/48 NS
Adjuvant therapy 30 53 51 47
Radiotherapy [n] 29 50 NS 48 46 NS
Chemotherapy [n] 12 19 NS 19 16 NS
Tamoxifen use [n] 25 38 NS 41 34 NS
doi:10.1371/journal.pone.0004223.t002
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institutional review board approval was not required. Accordingly,
patients were specifically asked for a verbal informed consent only,
and consequently no IRB number approval was requested. The
study was carried out according to the Declaration of Helsinki
principles and in agreement with the French laws on biomedical
research.
Immunohistochemistry
Breast tumor sections of 5 mm thickness were analyzed by
immunohistochemistry for NTSR1, NTS, ER, and PR staining,
using the following antibodies: a NTSR1 goat polyclonal antibody
(C-20 Santa Cruz USA), a NTS rabbit antibody (NA1230 Biomol,
USA), a ER-a monoclonal antibody (Santa Cruz), a PR monoclonal
antibody (Santa Cruz). Immunostaining was carried out on
deparaffinized sections using the streptavidin biotin peroxidase
complex method as described previously by Souaze ´e ta l[ 7 ] .A l l
slides were counterstained with hematoxylin. A semi-quantitative
estimation of the number of positive cellswas performed by counting
1 000 reactive and non-reactive cells in ten successive fields at the
original 2006magnification.
Figure 3. NTSR1 expression in IDCs and global survival duration. Kaplan-Maier analysis for global survival duration in both groups with low
(,80%) and high ($80%) NTSR1 expression. Probability of overall death for patients with high NTSR1 expression (n=38) versus patients with low
NTSR1 expression (n=68).
doi:10.1371/journal.pone.0004223.g003
Table 3. Prognosis factors and deaths stratified by NT-1
receptor expression in the invasive component of IDCs.
NT1 receptor
n=106
,80% .80% P
n=68 n=38
Positive estrogen receptor [n/number of
cases studied]
46/64 23/36 NS
Positive progesterone receptor [n/number
of cases studied]
46/63 25/36 NS
Tumor size (cm) [number of cases studied] 68 38
[mean (SD) 2.0861.35 2.7161.4 0.007
SBR grade [number of cases studied] 68 38
12 6 7
23 1 1 8
3 11 13 0.036
Number of invaded nodes[number of
cases studied]
66 38
[mean6SD] 0.8661.7 2.1163.4 0.05
Recurrence during follow-up [n/number
of cases studied]
13/67 13/38 0.09
Deaths during follow-up [n/number of
cases studied]
2/68 9/38 0.0025
Adjuvant therapy (102 cases studied) 65 37
Radiotherapy [n] 61 35 NS
Chemotherapy [n] 17 19 0.01
Tamoxifen use [n] 49 29 NS
NT [n/number of cases studied] 28/65 20/37 NS
doi:10.1371/journal.pone.0004223.t003
Table 4. Correlation of the subpopulation co-expressing NT
and NT1 receptor with the major prognosis factors.
NT invasive component
n=48
NT-1
receptor
NT-1
receptor P
,80% .80%
n=28 n=20
Positive estrogen receptor [n/number of
cases studied ]
24/27 12/20 0.049
Tumor size (cm) [mean6SD] 28 20
[number of cases studied] 2.0861.15 2.3761.16
SBR grade [number of cases studied] 28 20
11 4 3
21 2 1 0
3 2 7 0.011
doi:10.1371/journal.pone.0004223.t004
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Normal human breast epithelial cells (HBEC) were cultured as
previously described in Gompel et al. [29]. Additional biopsies of
normal breast tissues from 25 premenopausal women of various
ages (18–50 years) undergoing plastic surgery were obtained
according to the French regulations on clinical experimentation.
RNA extraction and RT-PCR
The protocols for total RNA extraction, reverse-transcription
reaction (RT), and PCR are documented in Souaze ´ et al [30]. RT
was performed on 1 mg of total RNA using a specific NTSR1
primer (59-GCTGACGTAGAAGAG-39) or 50 pmol of oligo dT
and oligo dN. The PCR amplification was performed on a 1:5 v/v
of the RT reaction using 25 pmol of each primer 59-CGTG-
GAGCTGTACAACTTCA-39 and 59-CAGCCAGCAGACCA-
CAAAGG-39 for NT1 receptor, and 59-AAGCACATGTTCC-
CTCTT-39 and 59-CATACAGCTGCCGTTTCAGA-39 for
NTS, and 1 unit of Taq polymerase (Applied Biosystems,
Courtaboeuf, France). The amplification profile consisted of
denaturation at 94uC for 30 s, annealing at 57uC for 45 s, and
extension at 72uC for 45 s. The PCR cycle were preceded by
denaturation at 95uC for 15 min and were followed by a final
extension at 72uC for 7 min.
Hormonal treatments
HBEC were synchronized for 40 h in Ham F10 phenol red free
medium containing 20 mM lovastatin. Synchronization was
stopped by adding 2 mM mevalonate to the hormone-containing
medium. Subsequently, cells were treated 48 h in a phenol red free
medium containing 5% of compatible human serum with 10 nM
estradiol (E2) with or without 1 mM ICI 182780.
Statistics
Analyses were processed with StatView Version 5 (Abacus
Concepts, Berkeley, CA., USA). Descriptive statistics were
performed for each variable; quantitative results are presented as
mean6SD and qualitative results are presented as a distribution of
a number of patients. To compare the two groups, x
2 test was used
for qualitative variables and t test for quantitative variables. A p
value,0.05 was accepted as significant. Survival analysis was
performed by Kaplan-Meier method and comparison with Log-
Rank test. For multivariate analysis, Cox model was performed
using R statistical package.
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